Abstract
Recent SARS-CoV-2 variants pose important concerns due to their higher transmissibility (1) and escape (2) from previous infections or vaccine-induced neutralizing antibodies (nAb). The receptor binding domain (RBD) of the Spike protein is a major nAb target (3), but data on its B cell epitopes are still lacking. Using a peptide microarray, we identified an immunodominant epitope (S415-429) recognized by 68% of sera from 71 convalescent Brazilians infected with the ancestral variant. In contrast with previous studies, we have identified a linear IgG and IgA antibody binding epitope within the RBD. IgG and IgA antibody levels for this epitope positively correlated with nAb titers, suggesting a potential target of antibody neutralizing activity. Interestingly, this immunodominant RBD region harbors the mutation hotspot site K417 present in P.1 (K417T) and B.1.351 (K417N) variants. In silico simulation analyses indicate impaired RBD binding to nAb in both variants and that a glycosylation in the B.1.351 417N could further hinder antibody binding as compared to the K417T mutation in P.1. This is in line with published data showing that nAb from either convalescents or anti-CoV-2 vaccinees are less effective towards B.1.351 than for P.1. Our data support the occurrence of immune pressure and selection involving this immunodominant epitope that may have critically contributed to the recent COVID-19 marked rise in Brazil and South Africa, and pinpoint a potential additional immune escape mechanism for SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by FAPESP project N. 2020/05256-7 and FINEP grant N. 01.20.0009.00.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by CAPPesq (Comissao de Etica Para Analise de Projetos de Pesquisa do HC-FMUSP) and CONEP (Comissao Nacional de Etica em Pesquisa) (CAAE: 30155220.3.0000.0068). All study participants signed informed consents.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
COVID-19 SP-Brazil Team: in alphabetical order: Aline Martins, André Kenji Honda, Andreia Cristina Kazue Kuramoto Takara, Ariane Cesario Lima, Cesar Manuel Remuzgo Ruiz, Cesar Sato, Deibs Barbosa, Fernanda Romano Bruno, Edgar Ruz Fernandes, Giuliana Xavier De Medeiros, Greyce Luri Sasahara, João Paulo Silva Nunes, Juliana de Souza Apostolico Andrade, Lucas Caue Jacintho, Luis Antonio Rodrigues Carneiro, Marco Antonio Stephano, Marcos Camargo Knirsch, Marcio Massao Yamamoto, Maria Lucia Carnevale Marin, Mirian Pinheiro Bruni, Rafael Ribeiro Almeida, Raquel Elaine de Alencar, Ricardo José Giordano, Roberta Liberato Pagni, Samar Freschi de Barros, Sandra Maria Monteiro, Simone Regina dos Santos.
Data Availability
No additional data.
